About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Biotechnology Law Report

Executive Editor: Christopher M. Holman

ISSN: 0730-031X • Published Bimonthly • Online ISSN: 1557-8704

Current Volume: 33

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Biotechnology Law Report invites the submission of original manuscripts covering all aspects of biotechnology law. Send manuscripts to Steven J. Zweig, Consulting Editor, with copy to Gerry J. Elman, Editor-in-Chief.  See below for their email address.

     

    Paper Submission

     

    Articles should be submitted in electronic form, as e-mail attachments to stevenjzweiglaw@gmail.com.  Please specify in the text of the e-mail the word processing format used in creating the manuscript.  Microsoft Word is preferred.

     
    References

     

    Using Blue Book format, please generate footnotes cited by superscript reference numerals throughout the text.  We reserve the right to modify style to conform to the Journal’s overall style.  Suggested readings or lists of other source materials may also be included in a final footnote.

     

    Permissions

     

    The author must obtain permission to reproduce from any copyrighted material. Written permission must be obtained from the original copyright holder (generally the publisher) of the journal or book concerned. An appropriate credit line and copyright notice should be included and a full citation should be included in the reference list.

     

    Reprints


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
     

    Publisher

     

    Biotechnology Law Report is published six times a year by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215.  Telephone: (914) 740–2100; fax: (914) 740–2101.

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

    Industrial Biotechnology

    Industrial Biotechnology

    The authoritative, peer-reviewed bimonthly research journal focused on biobased industrial and environmental products and processes reporting the science, business, and policy developments of the emerging global bioeconomy.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

    Cellular Reprogramming

    Cellular Reprogramming

    Cutting-edge techniques and the latest high-quality research on the etiology, development, and potential treatment of various diseases through reprogramming cellular mechanisms.

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

Browse All Publications »